Gliken (Glibenclamide)

Gliken is indicated for the oral treatment of type 2 diabetes mellitus when diet, exercise, and other non‑pharmacologic measures are insufficient to achieve glycemic control.

• Improves fasting and post‑prandial blood glucose levels.
• Can be used as monotherapy in patients newly diagnosed with type 2 diabetes.
• May be combined with metformin or other oral antidiabetic agents when additional glucose lowering is required.
• Often prescribed when a sulfonylurea is preferred due to cost or patient response considerations.
• May be considered in patients with stable renal function who do not require insulin therapy.

The safety profile of Gliken reflects the typical effects observed with sulfonylurea class medications.

Common

• Mild to moderate hypoglycemia, often occurring when meals are missed, delayed, or when alcohol is consumed.
• Gastrointestinal discomfort such as nausea, abdominal pain, dyspepsia, or loss of appetite.
• Gradual weight gain related to increased insulin secretion and caloric intake.
• Dermatologic reactions including rash, pruritus, or mild urticaria.

Serious

• Severe hypoglycemia that may cause confusion, seizures, loss of consciousness, or require emergency medical assistance.
• Allergic responses ranging from skin rash to angioedema and, in rare cases, anaphylactic shock.
• Hepatotoxicity presenting as jaundice, elevated transaminases, or hepatitis (uncommon).
• Acute pancreatitis characterized by persistent abdominal pain, nausea, and raised pancreatic enzymes (rare).

When prescribing Gliken, clinicians consider several precautions to minimize risk and ensure safe use.

• Assess renal and hepatic function before initiation and periodically during therapy.
• Use lower starting doses in elderly patients or those with reduced clearance.
• Advise patients to maintain regular meal patterns to avoid hypoglycemia.
• Monitor for signs of cardiovascular disease, as sulfonylureas may mask ischemic symptoms.
• Counsel women of childbearing potential about pregnancy risks and recommend effective contraception.
• Review concomitant medications for agents that potentiate hypoglycemia, such as certain antibiotics or antiretrovirals.
• Educate patients on recognizing early symptoms of hypoglycemia and appropriate corrective actions.

Gliken may interact with other medicines, affecting blood glucose levels or increasing the risk of adverse events.

Avoid

• Concurrent use with other sulfonylureas or meglitinides, which can cause additive hypoglycemia.
• Co‑administration with strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone) that raise glibenclamide plasma concentrations.
• Combining with insulin or high‑dose metformin without dose adjustment, due to heightened hypoglycemic risk.
• Avoid use with high‑dose corticosteroids, which may exacerbate hyperglycemia and counteract Gliken's effect.

Use with caution

• Beta‑blockers, which may mask hypoglycemia symptoms.
• Thiazide diuretics, which can alter glucose tolerance.
• Oral contraceptives, as hormonal changes may affect glycemic control.
• Renal impairment drugs such as ACE inhibitors may require dose modification and closer monitoring.